Figure 2From: Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancerPeptide specific CTL response in case 9. Strong CTL responses specific to KIF20A-66 peptide were obtained at the time of 2Â months after vaccination. The responses were kept strong positive during 2Â years of the observation period. The number of the spots specific to peptide was calculated by subtracting the spot number in control wells from that in peptide-pulsed TISI cells.Back to article page